文献速递乳腺癌

多灶性和多中心性乳腺癌的瘤间分子表型异质性及预后分析

[Intertumoral heterogeneity of molecular phenotype and analysis of prognosis in multifocal and multicentric breast cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2016-01-01

该研究回顾性分析2009年1月至2009年12月郑州大学附属肿瘤医院146例多灶性/多中心性乳腺癌患者的临床及随访资料,采用Kaplan-Meier曲线比较分子表型异质性与同质性肿瘤患者的生存差异,Cox比例风险回归计算风险比。结果显示,分子表型异质性组5年疾病特异生存率显著低于同质性组(58.3% vs 78.7%,P=0.037),复发风险更高(HR=2.130,95%CI=1.027-4.420;P=0.042)。

要点

  • 146例多灶性/多中心性乳腺癌中,瘤间分子表型异质性24例(16.4%)。
  • 分子表型异质性组5年疾病特异生存率58.3%,同质性组78.7%,差异有统计学意义(P=0.037)。
  • 分子表型异质性组复发风险更高(HR=2.130,95%CI=1.027-4.420;P=0.042)。

核心结论

  • 多灶性乳腺癌中分子表型异质性患者无病生存期在统计学上显著缩短。
  • 对额外癌灶进行表型分析并据此制定恰当治疗决策可能降低复发或转移风险、改善患者结局。

研究设计与样本

  • 回顾性分析2009年1月至2009年12月郑州大学附属肿瘤医院收治的146例多灶性/多中心性乳腺癌患者的临床及随访资料。
  • 采用Kaplan-Meier曲线比较分子表型异质性与同质性患者的生存,以及组织学类型和分级异质性与同质性患者的生存。
  • 采用Cox比例风险回归计算相应的风险比。

主要发现

  • 146例中组织学类型异质性16例(11.0%),组织学分级异质性10例(6.8%),瘤间分子表型异质性24例(16.4%)。
  • 组织学类型和分级异质性与同质性患者5年无病生存率分别为75.0%与77.3%,差异无统计学意义(P=0.808)。
  • 分子表型异质性组与同质性组5年疾病特异生存率分别为58.3%与78.7%,差异有统计学意义(P=0.037)。
  • 分子表型异质性组复发风险更高(HR=2.130,95%CI=1.027-4.420;P=0.042)。
  • 对额外癌灶进行表型分析影响了多达16例(11.0%)患者的治疗决策。

临床怎么用

  • 作者认为,对额外癌灶进行表型分析并据此制定恰当治疗决策可能降低复发或转移风险、改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study was designed to investigate the prognostic implications of the intertumoral heterogeneity of molecular phenotype in multifocal and multicentric breast cancer (MMBC). Methods: The clinical and follow-up data of 146 patients with MMBC from Jan.2009 to Dec. 2009 treated in Tumor Hospital Affiliated to Zhengzhou University were retrospectively analyzed. We used Kaplan-Meier curves to compare the survivals of patients who had tumors with molecular phenotypic heterogeneity and patients who had multifocal homogeneous tumors in molecular phenotype, and the survivals of patients who had heterogeneous tumor type and grade and who had homogeneous tumor type and grade.The corresponding hazard ratio was calculated by Cox proportional-hazards regression. Results: Intertumoral heterogeneity in histological type and grade of multiple breast cancer was detected in 16 of 146 patients (11.0%) and in 10 of 146 patients (6.8%), respectively. Interfocal heterogeneous molecular phenotype of multiple breast cancer was detected in 24 of 146 patients (16.4%). There was no significant difference in 5-year disease-free survival in multifocal cancer patients who had heterogeneous histological type and grade and who had homogeneous type and grade tumors (75.0% vs. 77.3%, P=0.808). Multifocal cancers patients who had heterogeneous tumorsin molecular phenotype compared with those with homogeneous tumors in molecular phenotype had worse 5-year disease-specific survival (78.7% vs. 58.3%, P=0.037), and had a greater risk of recurrence (HR=2.130, 95%CI=1.027-4.420; P=0.042). Phenotyping the additional cancer foci influenced the therapeutic decision in up to 16 patients(11.0%). Conclusions: Multifocal breast cancer patients who had heterogeneous tumors in molecular phenotype have a statistically significantly shorter disease-free survival. Phenotyping the additional cancer foci and managing with proper therapeutic decision may reduce the risk of recurrence or metastasis, and improve the outcomes of the patients.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Duan YS, Mao QX, Li LF, et al. [Intertumoral heterogeneity of molecular phenotype and analysis of prognosis in multifocal and multicentric breast cancer]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998441. doi:10.3760/cma.j.issn.0253-3766.2016.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。